Esperion Therapeutics reported $12.47M in Gross Profit on Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Alnylam Pharmaceuticals ALNY:US USD 223.19M 39.18M
Amarin AMRN:US USD 65.94M 7.31M
Amgen AMGN:US USD 5.09B 28M
Biogen BIIB:US USD 2.04B 66.1M
Biomarin Pharmaceutical BMRN:US USD 389.06M 21.62M
Daiichi Sankyo 4568:JP JPY 242.5B 207M
Eli Lilly And LLY:US USD 5.75B 391.2M
Esperion Therapeutics ESPR:US USD 12.47M 2.81M
Halozyme Therapeutics HALO:US USD 161.66M 43.24M
Intercept Pharmaceuticals ICPT:US USD 77.16M 5.72M
Intra Cellular Therapies ITCI:US USD 66.02M 15.09M
IONIS PHARMACEUT IONS:US USD 158.25M 29.21M
Merk MRK:US USD 10.47B 610M
Moderna Inc MRNA:US USD 2.26B 1.1B
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Pfizer PFE:US USD 14.47B 2.08B
Ptc Therapeutics PTCT:US USD 203.12M 47.23M
Regeneron Pharmaceuticals REGN:US USD 2.87B 255.4M
Sarepta Therapeutics SRPT:US USD 190.32M 5.38M
Seattle Genetics SGEN:US USD 402.18M 10.78M
United Therapeutics UTHR:US USD 478.8M 41.6M